| Name |
Administration |
Indication |
| Abraxane® (paclitaxel
protein-bound particles) |
non-SAI |
Cancer |
| Actemera® (tocilizumab) |
non-SAI |
Rheumatoid Arthritis |
| Actimmune® (interferon
gamma-1b) |
SAI |
Chronic Granulomatous Disease |
| Adagen® (pegademase
bovine) |
non-SAI |
Severe Combined Immunodeficiency |
| Adcirca™ (tadalafil) |
oral |
Pulmonary Arterial Hypertension |
| Advate® (antihemophilic
factor [recombinant]) |
non-SAI |
Hemophilia |
| Afinitor® (everolim
us) |
oral |
Cancer |
| Aldurazyme® (laronidase) |
non-SAI |
Metabolic disorder (Mucopolysccharidosis-1) |
| Alphanate® (antihemophilic
factor [human]) |
non-SAI |
Hemophilia |
| AlphaNine®SD
(coagulation factor IX [human]) |
non-SAI |
Hemophilia |
| Amevive® (alefacept) |
non-SAI |
Psoriasis |
| Ampyra ™ (dalfampridine) |
oral |
Multiple Sclerosis |
| Apokyn® (apomorphine
hydrochloride) |
SAI |
Parkinson's Disease |
| Aralast® (alpha[1]-proteinase
inhibitor [human]) |
non-SAI |
Lung disease (Alpha-1 Antitrypsin Deficiency) |
| Aranesp® (darbepoetin
alfa) |
SAI |
Anemia |
| Arcalyst® (rilonacept) |
SAI |
Inflammatory disease (Cryopyrin-Associated Periodic Syndrome) |
| Arixtra® (fondaparinux
sodium) |
SAI |
Deep Vein Thrombosis |
| Arranon® (nelarabine) |
non-SAI |
Cancer |
| Arzerra ™ (ofatum
umab) |
non-SAI |
Cancer |
| Atryn® (antithrombin
[recombinant]) |
non-SAI |
Clotting disorder (Hereditary Antithrombin Deficiency) |
| Avastin® (bevacizumab) |
non-SAI |
Cancer |
| Avonex® (interferon
beta-1a) |
SAI |
Multiple Sclerosis |